Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Immunovant Q2 2026 Results: Net Loss of $97.2M, Loss Narrows

Immunovant reported a net loss of $97.2 million for the quarter ended September 30, 2026, compared to $126.5 million in the prior year period. The company maintained a strong liquidity position with $722.3 million in cash and cash equivalents, while research and development expenses remained the primary driver of operating costs at $85.0 million for the quarter.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Profit before tax-97.2-125.9
Net income-97.2-126.5
EPS (diluted, $ a share)$-0.47$-0.73

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: IMVT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Immunovant, Inc.: key numbers

Share price
$33.28Close, Nov 16
Market cap
$6.89B
Shares outstanding
206.95MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Immunovant, Inc.

All →
4:42 PM ET Form 4
Insider Selling

Immunovant Insider Atul Pande Sells $108K of Stock

Atul Pande sold 3,000 shares of Immunovant, Inc. at $36.00 a share, worth $108K in total on Nov 11, 2026. Shares held after the trade: 116,731 (-2.5%).

Value
$108K
Shares
3,000
Price
$36.00
Holding change
-2.5%
Trade date
Nov 11, 2026
7:10 AM ET 8-K
Financial Results

Immunovant Financial Results

Immunovant reported financial results for its fiscal second quarter ended September 30, 2026, and announced positive topline data from a potentially registrational trial of IMVT-1402 in rheumatoid arthritis. The company ended the quarter with $722.3 million in cash and cash equivalents, which it expects will fund operations into 2028.

Term
Q2 2026
4:37 PM ET Form 4
Insider Selling

Immunovant CFO Tiago Girao Sells $188K of Stock

Tiago Girao, CFO, sold 6,606 shares of Immunovant, Inc. at $28.50 a share, worth $188K in total on Oct 28, 2026. Shares held after the trade: 234,192 (-2.7%).

Value
$188K
Shares
6,606
Price
$28.50
Role
CFO
Holding change
-2.7%
Trade date
Oct 28, 2026
5:06 PM ET Form 4
Insider Selling

Immunovant CTO Jay S. Stout Sells $122K of Stock

Jay S. Stout, CTO, sold 3,809 shares of Immunovant, Inc. at $32.06 a share, worth $122K in total on Oct 7, 2026. Shares held after the trade: 201,532 (-0.8%).

Value
$122K
Shares
3,809
Average price
$32.06
Role
CTO
Holding change
-0.8%
Trade date
Oct 7, 2026
5:05 PM ET Form 4
Insider Selling

Immunovant CLO Tuyl Christopher Van Sells $42.5K of Stock

Tuyl Christopher Van, CLO, sold 1,327 shares of Immunovant, Inc. at $32.06 a share, worth $42.5K in total on Oct 7, 2026. Shares held after the trade: 175,218 (-0.8%).

Value
$42.5K
Shares
1,327
Price
$32.06
Role
CLO
Holding change
-0.8%
Trade date
Oct 7, 2026
5:04 PM ET Form 4
Insider Selling

Immunovant COO Melanie Gloria Sells $71.8K of Stock

Melanie Gloria, COO, sold 2,241 shares of Immunovant, Inc. at $32.06 a share, worth $71.8K in total on Oct 7, 2026. Shares held after the trade: 217,060 (-1.0%).

Value
$71.8K
Shares
2,241
Price
$32.06
Role
COO
Holding change
-1.0%
Trade date
Oct 7, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.